CymitQuimica logo

CAS 960201-81-4: rel-6,7-Dimethyl (1R,5R,6R,7S)-4-oxo-8-(phenylmethyl)-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylate

Formula:C18H19NO5
InChI:InChI=1/C18H19NO5/c1-23-17(21)14-12-8-9-13(20)16(15(14)18(22)24-2)19(12)10-11-6-4-3-5-7-11/h3-9,12,14-16H,10H2,1-2H3/t12-,14-,15-,16+/s2
InChI key:InChIKey=PYZQFEIRZQYUJQ-OYSMYPGONA-N
SMILES:C(N1[C@@]2([C@H](C(OC)=O)[C@H](C(OC)=O)[C@]1(C=CC2=O)[H])[H])C3=CC=CC=C3
Synonyms:
  • rel-6,7-Dimethyl (1R,5R,6R,7S)-4-oxo-8-(phenylmethyl)-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylate
  • 8-Azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid, 4-oxo-8-(phenylmethyl)-, 6,7-dimethyl ester, (1R,5R,6R,7S)-rel-
  • SD 1008
Sort by

Found 2 products.
  • SD 1008

    CAS:
    SD 1008 is a histone lysine modulator that has been shown to improve memory in animal models of Alzheimer's disease. It works by binding to the active site of the enzyme acetylcholinesterase, which breaks down the brain chemical acetylcholine. SD 1008 also reduces virus-induced cell degranulation and synapses in mouse brains. It is a conjugate of pyridine compounds with polymer chains that signal transducers and are targeted for cancer therapy. The structure of SD 1008 is similar to other drug molecules that have been developed for cancer treatment, including drugs targeting integrin receptors. This similarity may be useful when treating cancers that express this receptor as it may help reduce side effects caused by these drugs.
    Formula:C18H19NO5
    Purity:Min. 95%
    Molecular weight:329.35 g/mol

    Ref: 3D-KNB20181

    50mg
    879.00€
    100mg
    1,152.00€
  • SD 1008

    CAS:
    SD 1008 is a JAK2/STAT3 signaling pathway inhibitor. SD 1008 inhibits activation of STAT3, JAK2, and Src.
    Formula:C18H19NO5
    Purity:98%
    Color and Shape:Solid
    Molecular weight:329.35

    Ref: TM-T23340

    10mg
    To inquire